Skip to main content
S&P 5007,353.73-4.36%DOW51,523.06-3.44%NASDAQ24,315.00-5.52%BTC$76,277.00-5.40%ETH$2,243.42-7.45%GOLD$4,109.40-0.10%OIL$91.06+0.60%
Smart Investors Daily
SID Premium
HS

NASDAQ · HSCSW

HeartSciences Inc.

Healthcare · Medical - Devices

$0.07

Up+$0.01 (+20.96%)

Updated Nov 6, 2026, 12:57 AM

SID Score

4.0/10

Composite research score

Smart Money

—

Institutional and insider signal

Market cap
191.88K
P/E ratio
-0
Dividend yield
0.00%
52-week range
$0.04 – $0.18
Volume
341
Avg. volume
4.54K

Price performance · HSCSW

HSCSW price history

1M range · 11 trading sessions · Daily adjusted prices

Prices through Nov 3, 2026

HSCSW closed at $0.07 after 11 trading sessions, up 4.56% for the selected period.

Last close
$0.07
Period change
+4.56%
Period low
$0.05
Period high
$0.13
Daily close
View OHLC price history
HSCSW OHLC price history, latest 40 sessions
DateOpenHighLowCloseVolume
Nov 3, 2026$0.105$0.105$0.071$0.0711341
Nov 2, 2026$0.12$0.12$0.12$0.12239
Oct 30, 2026$0.1009$0.125$0.07$0.0718.15K
Oct 29, 2026$0.1006$0.1009$0.0697$0.10093.07K
Oct 27, 2026$0.0863$0.0865$0.086$0.0869.7K
Oct 26, 2026$0.0634$0.18$0.0622$0.1339.67K
Oct 21, 2026$0.0798$0.0798$0.046$0.04636.75K
Oct 15, 2026$0.06$0.0602$0.06$0.06024.27K
Oct 12, 2026$0.068$0.068$0.068$0.0681.67K
Oct 9, 2026$0.07$0.07$0.0681$0.0681906
Oct 8, 2026$0.0681$0.0681$0.068$0.0689.84K

Latest HSCSW news

The latest Smart Investors Daily articles mentioning HSCSW.

Stock researchCompany · Overview

HSCSW research

Overview

Company profile and research snapshot.

Company profile

HeartSciences Inc is an artificial intelligence (AI)-powered medical technology company focused on transforming ECGs/EKGs to save lives through earlier detection of heart disease. Its objective is to improve healthcare by making it a far more valuable cardiac screening tool, particularly in frontline or point-of-care clinical settings. It is developing a suite of AI-ECG diagnostic solutions for use in any healthcare care setting, either via MyoVista Insights cloud-platform using one of the millions of ECG devices currently in clinical use or via MyoVista wavECG Device.

Visit company website

Analyst outlook

Consensus and target data currently published for this company.

Consensus
—
Average target
—
Implied upside
—
Analysts
—
Open full forecast

News briefing

No generated briefing is available yet.

Yahoo · Oct 21, 2026

HeartSciences Files Definitive Proxy Statement for Proposed Business Combination with Fortitude Mining

Shareholder Special Meeting Scheduled for November 19, 2026Definitive proxy statement filed with the SEC, marking an important milestone toward completion of the proposed transactionHeartSciences Board of Directors unanimously recommends shareholders vote FOR the transaction-related proposalsProposed combination expected to establish a publicly traded, vertically-integrated digital asset mining platform focused on Zcash, subject to shareholder approval and other closing conditions SOUTHLAKE, Tex

Yahoo · Oct 6, 2026

HeartSciences Receives FDA 510(k) Clearance for its MyoVista® wavECGTM Device

Southlake, TX, Oct. 06, 2026 (GLOBE NEWSWIRE) -- HeartSciences Inc. (Nasdaq: HSCS; HSCSW) (“HeartSciences” or the “Company”), a healthcare information technology (“HIT”) company focused on advancing electrocardiography (“ECG” or “EKG”) through the integration of artificial intelligence (“AI”), today announced that the U.S. Food and Drug Administration (“FDA”) has granted 510(k) clearance (K260005) for its MyoVista® wavECGTM device as a 12-lead resting electrocardiograph. The clearance covers the

AI research layers

Interpretive context generated from the platform’s current data sources.

No results

AI research layers have not been published yet.

Featured By